TGM2 and cranioectodermal dysplasia: In conclusion, the strategy to inhibit TG2 activity as a key upstream effector in gluten-induced immune activation in CeD, which has been proven efficient in the clinical study, was mechanistically buttressed by our transcriptomic analysis of the duodenal biopsies of individuals treated or not treated with ZED1227.